A Multicenter, Single-Arm, Prospective, Phase 3b Study to Evaluate Safety and Efficacy of Glecaprevir/Pibrentasvir 8-Week Treatment in Adults With Acute Hepatitis C Virus Infection

Conference Reports for NATAP

The Liver Meeting
AASLD 2024
Nov 15-19,
San Diego, CA


A Multicenter, Single-Arm, Prospective, Phase 3b Study to Evaluate Safety and Efficacy of Glecaprevir/Pibrentasvir 8-Week Treatment in Adults With Acute Hepatitis C Virus Infection

	AASLD 2024 Nov 15-19 San Diego